Dr. Reddy’s Receives USFDA Form 483 with Seven Observations After Pre-License Inspection of Hyderabad Biologics Facility
Dr. Reddy’s Laboratories Limited has announced that the United States Food and Drug Administration (USFDA) has completed a Pre-License Inspection (PLI) at its biologics manufacturing facility located in Bachupally, Hyderabad. Following the inspection, the USFDA issued a Form FDA 483 containing seven observations.
The company disclosed the development through a regulatory filing to the stock exchanges and stated that it will respond to all observations within the timeline specified by the USFDA.
USFDA Inspection Timeline
The Pre-License Inspection (PLI) was conducted over a period of ten days.
Inspection Details
| Particular | Details |
|---|---|
| Company | Dr. Reddy’s Laboratories Ltd. |
| Facility | Bachupally Biologics Manufacturing Facility |
| Location | Hyderabad, Telangana |
| Regulatory Authority | United States Food and Drug Administration (USFDA) |
| Inspection Type | Pre-License Inspection (PLI) |
| Inspection Period | June 16 – June 25, 2026 |
| Outcome | Form FDA 483 Issued |
| Total Observations | 7 |
What is a Pre-License Inspection (PLI)?
A Pre-License Inspection (PLI) is conducted by the USFDA before granting approval for manufacturing facilities that produce pharmaceutical or biological products intended for the U.S. market.
During the inspection, FDA investigators assess:
- Manufacturing processes
- Quality management systems
- Data integrity
- Documentation practices
- Good Manufacturing Practices (GMP) compliance
- Product quality controls
- Facility operations
The objective is to verify that the facility consistently produces safe, effective, and high-quality medicines.
USFDA Issues Form FDA 483
At the conclusion of the inspection, the USFDA issued Form FDA 483 with seven observations.
The company has clarified that it will submit detailed responses addressing each observation within the prescribed regulatory timeline.
Dr. Reddy’s has not disclosed the specific nature of the seven observations in its stock exchange filing.
What is Form FDA 483?
Form FDA 483 is issued when FDA investigators identify conditions that may require corrective action during an inspection.
It is important to understand that receiving a Form 483:
- Does not mean the company has violated the law.
- Does not represent a final regulatory decision.
- Does not automatically affect product approvals.
- Provides an opportunity for the company to implement corrective and preventive actions (CAPA).
After receiving the observations, the company is expected to submit a detailed response explaining how each issue will be resolved.
Company Response
Dr. Reddy’s Laboratories stated that it will:
- Carefully review all seven observations.
- Implement corrective and preventive actions where required.
- Submit a comprehensive response to the USFDA within the stipulated timeline.
The company has not indicated any impact on ongoing operations or product supply.
Previous USFDA Inspections
The latest inspection follows earlier regulatory inspections at the same facility.
According to the company, this disclosure continues its previous communications regarding inspections conducted in:
- October 2023
- September 2025
- June 2026 (Current Pre-License Inspection)
This indicates continued regulatory engagement with the Bachupally biologics manufacturing site.
Why This Inspection Matters
USFDA inspections are a routine and essential part of ensuring pharmaceutical quality and patient safety.
Successful resolution of Form 483 observations is important because it helps companies:
- Maintain regulatory compliance
- Strengthen quality systems
- Support future product approvals
- Continue supplying medicines to international markets
For biologics manufacturers like Dr. Reddy’s, regulatory compliance is critical to expanding their global portfolio.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is one of India’s leading multinational pharmaceutical companies engaged in:
- Generic medicines
- Biosimilars
- Active Pharmaceutical Ingredients (APIs)
- Branded formulations
- Over-the-counter (OTC) products
- Specialty pharmaceuticals
The company exports medicines to several international markets, including the United States, Europe, and emerging economies.
Key Highlights
- USFDA completed a Pre-License Inspection at Dr. Reddy’s Bachupally biologics facility.
- Inspection was conducted from June 16 to June 25, 2026.
- USFDA issued Form FDA 483 containing seven observations.
- Dr. Reddy’s will respond within the prescribed timeline.
- The company has not disclosed the details of the observations.
- A Form 483 is not a final regulatory action or compliance determination.
Conclusion
The completion of the USFDA Pre-License Inspection at Dr. Reddy’s Bachupally biologics facility represents another important regulatory milestone for the company. Although the inspection concluded with seven Form 483 observations, this is a common part of the FDA inspection process and does not imply regulatory action or product rejection.
The focus now shifts to Dr. Reddy’s response, as the company works to address the observations through appropriate corrective and preventive actions. Investors, healthcare professionals, and industry stakeholders will closely monitor future updates from both the company and the USFDA.
Recommended Products
